[1] Stein IF,Leventhal NL. Amenorrhea associated with bilateral polycystic ovaries[J]. Am J Obstet Gynecol,1935,29: 181-191. [2] Azziz R, Woods KS, Reyna R,et al. The prevalence and features of the polycystic ovary syndrome in an unselected population[J]. J Clin Endocrinol Metab,2004,89: 2745-2749. [3] Knochenhauer ES, Key TJ, Kahsar-Miller M,et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study[J]. J Clin Endocrinol Metab,1998,83: 3078-3082. [4] Diamanti-Kandarakis E, Kouli CR, Bergiele AT,et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile[J]. J Clin Endocrinol Metab,1999,84: 4006-4011. [5] Asuncion M, Calvo RM, San Millan JL,et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from Spain[J]. J Clin Endocrinol Metab,2000,85: 2434-2438. [6] Michelmore KF, Balen AH, Dunger DB,et al. Polycystic ovaries and associated clinical and biochemical features in young women[J]. Clin Endocrinol (Oxford),1999,51: 779-786. [7] Goodarzi MO, Quin ones MJ, Azziz R,et al. Polycystic ovary syndrome in Mexican Americans: prevalence and association with the severity of insulin resistance[J]. Fertil Steril,2005,84: 766-769. [8] Rong Li, Qiufang Zhang, Dongzi Yang,et al. Prevalence of polycystic ovary syndrome in women in China: A Large Community-Based Study[J]. Hum Reprod,2013, 7: 1-8. [9] Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility[M]. 7th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2005:123. [10] Laven JS,Imani B, Eijkemans MJ,et al. New approach to polycystic ovary syndrome and other forms of anovulatory infertility[J].Obstet Gynecol Surv,2002, 57 (11): 755-767. [11] Bili H, Laven J, Imani B,et al. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years[J].Eur J Endocrinol,2001, 145 (6): 749 755. [12] The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J]. Hum Reprod,2004,19 (1): 41-47. [13] Li R, Qiao J, Yang D,et al.Epidemiology of hirsutism among women of reproductive age in the community: asimplifiedscoringsystem[J]. Eur J Obstet Gynecol Reprod Biol,2012, 163(2): 165 169. [14] Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome[J]. Med J Aust,2004,180 (3): 132-137. [15] Imani B, Eijkemans MJ, de Jong FH,et al.Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility[J].J Clin Endocrinol Metab,2000,85 (2): 676-682. [16] Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome[J]. Fertil Steril,2004,82: 661-665. [17] DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment[J]. Fertil Steril,2005,83: 1454-1460. [18] Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome[J].Diabetes ,1989,38 (9): 1165-1174. [19] American Diabetes Association.Consensus Development Conference on Insulin Resistance, 5-6 November 1997[J].Diabetes Care, 1998, 21 (2): 310-314. [20] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J]. JAMA ,2001,285 (19): 2486-2497. [21] Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up[J]. J Clin Epidemiol, 1998,51: 581-586. [22] Wild R, Painter P, Coulson P, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metabl,1985, 61: 946-951. [23] Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term followup[J]. J Clin Epidemiol ,1998,51: 581-586. [24] Hahn S, Tan S, Elsenbruch S,et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in north Rhine-Westphalia[J]. Horm Metab Res,2005,37: 438-444. [25] Pasquali R, Casimirri F, Venturoli S, et al. Body fat distribution has weight-independent effects on clinical, hormonal, and hirsutmetabolic features of women with polycystic ovary syndrome[J]. Metab Clin Exp,1994,43 (6): 706-713. [26] Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab,2001,86:1175-1180. [27] Fauser BC, Tarlatzis BC, Rebar RW,et al. et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J]. Fertil Steril,2012,97(1):28-38. |